Clinical Practice Guideline

Erectile Dysfunction

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction

(Endorsed, 2011)

The following guideline on Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction was developed by the American College of Physicians and endorsed by the AAFP.

Summary of Recommendations

  • The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have
    a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).
  • The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence).
  • The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

These guidelines are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute the individual judgment brought to each clinical situation by the patient’s family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These guidelines are only one element in the complex process of improving the health of America. To be effective, the guidelines must be implemented.